Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: CADL) | Delayed: 8.03 -0.35 (4.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.38 | 52 Week High | $ | |||
| Open | $8.33 | 52 Week Low | $ | |||
| Day High | $8.33 | P/E | N/A | |||
| Day Low | $7.91 | EPS | $ | |||
| Volume | 1,184,713 | |||||
